echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Phase II clinical trial application of Celinisolone for the treatment of MF by Deqi Pharmaceuticals was accepted by the NMPA

    The Phase II clinical trial application of Celinisolone for the treatment of MF by Deqi Pharmaceuticals was accepted by the NMPA

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Deck Pharmaceuticals recently announced that the National Medical Products Administration (NMPA) has accepted the world's first oral XPO1 inhibitor selinexor in a phase II clinical trial of monotherapy for patients with myelofibrosis (MF) in China


    The trial is a phase II, randomized, open-label, multi-center clinical study that evaluates the safety of Celinisole compared with doctor-chosen (PC) treatment in MF patients who have been treated with JAK1/2 inhibitors for at least 6 months Sex and efficacy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.